PFKP和CD133在胃癌组织中的表达及临床意义

The significance and expression of PFKP and CD133 in gastric cancer

目的探讨PFKP和CD133在胃癌组织中的表达及相关性,并分析两者表达与胃癌临床病理特征和预后的关系。方法检索癌症基因组图谱(TCGA)数据库中PFKP和CD133的表达情况及与预后的关系。收集2018年1月至2018年6月112例胃癌患者的癌组织和癌旁组织石蜡切片标本。采用免疫组化En Vision法检测上述组织中PFKP和CD133的表达;分析两者表达的相关性,及与临床病理特征和无进展生存期(PFS)的关系;Western blotting检测进一步确认胃癌组织中PFKP和CD133的表达水平。结果 TCGA数据库中,PFKP与CD133在415例胃癌组织中的表达水平均显著高于34例正常组织(P<0.01)。不同PFKP和CD133表达患者总生存时间的差异无统计学意义(P<0.05)。免疫组化检测显示,胃癌组织中PFKP和CD133的阳性表达率分别为81.2%(91/112)和67.9%(76/112),高于癌旁组织的34.8%(39/112)和27.7%(31/112),差异有统计学意义(P均<0.001)。Western blotting检测显示,胃癌组织中PFKP和CD133的表达水平显著高于癌旁组织(PFKP:0.212±0.034vs.0.069±0.01,P=0.001;CD133:1.182±0.107vs.0.403±0.035,P=0.000);胃癌组织中PFKP与CD133的表达呈正相关(r=0.547,P<0.001)。胃癌组织中PFKP表达与肿瘤直径、分化程度和Lauren分型有关(P<0.05);CD133表达与Lauren分型、分化程度、浸润深度、淋巴结转移和TNM分期有关(P<0.01)。全组中位PFS为31.0个月,其中PFKP阳性表达患者的中位PFS为31.0个月,阴性表达者为40.0个月,两者比较差异无统计学意义(P=0.511);CD133阳性表达患者的中位PFS为29.5个月,阴性表达者中位PFS未达到,两者比较差异无统计学意义(P=0.191)。结论胃癌组织中PFKP和CD133表达水平上升,两者表达呈正相关,PFKP可能在胃癌干细胞生物学行为中具有一定作用。

Objective To explore the expression of PFKP and CD133 in gastric cancers, and their expression with clinicopathologic factors and prognosis.Methods The expression of PFKP and CD133 and their relationship with prognosis were searched in The Cancer Genome Atlas(TCGA) database. A total of 112 paraffin-embedded tissue samples of gastric cancer and paired adjacent tissues were collected from January 2018 to June 2018. Immunohistochemistry was performed to investigate the PFKP and CD133 expression in the above tissues. The correlation of PFKP and CD133 expression with clinicopathologic factors and progressionfree survival(PFS) was analyzed. Western blotting was used to determine the levels of PFKP and CD133 in gastric and adjacent tissues.Results In TCGA database, the expression level of PFKP and CD133 in 415 gastric cancer tissues was significantly higher than that of 34 normal tissues(P< 0. 01). There was no significant difference in the overall survival of patients with different expressions of PFKP and CD133(P<0. 05). The positive rate of PFKP and CD133 in gastric cancer was 81. 2%(91/112)and 67. 9%(76/112), significantly higher than 34. 8%(39/112)and 27. 7%(31/112)in adjacent tissues(P<0. 001) by immunohistochemistry.Western blotting test showed that the protein leval of PFKP and CD133 was remarkably higher in gastric cancer than that in adjacent tissues(PFKP: 0. 212±0. 034 vs.0. 069±0. 01,P= 0. 001;CD133:1. 182±0. 107 vs.0. 403±0. 035,P= 0. 000). The expression of PFKP was positively correlated to CD133(r= 0. 547,P<0. 001). The expression of PFKP was related to tumor size, differentiation and Lauren classification(P<0. 05), while the expression of CD133 was correlated to Lauren classification, differentiation, infiltration,lymph node metastasis and TNM stages(P<0. 01). The median PFS of the whole group was 31. 0 months. For patients with PFKP positive expression, the median PFS was 31. 0 months, and that for patients with PFKP negative expression was 40. 0 months(P=0. 511);the median PFS was 29. 5 months in CD133 positive expression patients and that of CD133 negative expression patients was not reached(P= 0. 191).Conclusion The expression levels of PFKP and CD133 in gastric cancer tissues are increased, and there is a positive correlation between them. PFKP may play a role in the biology of gastric cancer stem cells.